Objetivo Colorectal cancer (CRC) was diagnosed in 1.23 million people worldwide (EU 333,000) in 2008 and 608,000 (EU 148,000) died of the disease. While some new treatments have been advanced in CRC many have failed clinical testing; metastatic CRC is still largely incurable.In CRC, Cancer Stem Cells (CSC) are responsible for tumour progression and resistant to standard chemotherapies. The Wnt signal transduction cascade controls normal colon physiology but also CSC maintenance. Deregulation of Wnt and other mitogenic pathways results in formation of aggressive tumours with metastatic potential. Novel combinatorial drugs targeting CSCs are required to address signalling redundancy and subvert resistance and escape mechanisms. However to test them effectively better drug screening tools must be developed. The high failure rate in cancer drug research has been linked to the poor predictive capacity of drug screening models for cancer and the inability to select the right patients for treatment.In SUPPRESSTEM, novel antibody-based therapeutics will be designed to modulate the Wnt pathway externally in combination with mitogenic receptors resulting in specific inhibition of CSCs with minimal toxicity on healthy tissue. The likelihood of clinically translating these goals will be enhanced because testing will be performed on relevant human patient material (both tumour and normal) using organoid technology and novel imaging readouts. In depth analysis of the phenotype of responsive organoids (patient material) will be used to identify a lead product.Successful execution of SUPPRESSTEM will provide an innovative drug product and drug screening tool ready for clinical validation that ultimately will increase the life expectancy and quality of cancer patients. Funding of SUPPRESSTEM will enable three research-focused SME’s to establish an innovative drug discovery paradigm with broad application in the cancer drug development. Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesclinical medicineoncologycolorectal cancermedical and health sciencesbasic medicinephysiology Programa(s) FP7-HEALTH - Specific Programme "Cooperation": Health Tema(s) HEALTH.2013.0-1 - Boosting the translation of health research projects' results into innovative applications for health Convocatoria de propuestas FP7-HEALTH-2013-INNOVATION-2 Consulte otros proyectos de esta convocatoria Régimen de financiación CP-FP - Small or medium-scale focused research project Coordinador MERUS BV Aportación de la UE € 3 229 540,60 Dirección PADUALAAN 8 133 3584CH UTRECHT Países Bajos Ver en el mapa Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Shelley Margetson (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos Participantes (4) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW Países Bajos Aportación de la UE € 1 122 911,00 Dirección KLOVENIERSBURGWAL 29 HET TRIPPENHUIS 1011 JV AMSTERDAM Ver en el mapa Región West-Nederland Noord-Holland Groot-Amsterdam Tipo de actividad Research Organisations Contacto administrativo Don Van Velzen (Mr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos OCELLO BV Países Bajos Aportación de la UE € 892 151,00 Dirección J H OORTWEG LEIDEN BIOPARTNER 21 2333 CH LEIDEN Ver en el mapa Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Leo Price (Dr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA) España Aportación de la UE € 338 346,80 Dirección CARRER BALDIRI REIXAC 10-12 PARC SCIENTIFIC DE BARCELONA 08028 Barcelona Ver en el mapa Región Este Cataluña Barcelona Tipo de actividad Research Organisations Contacto administrativo Raquel Furio (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos GENOME RESEARCH LIMITED Reino Unido Aportación de la UE € 370 369,60 Dirección WELLCOME SANGER INSTITUTE WELLCOME GENOME CAMPUS HINXTON CB10 1SA SAFFRON WALDEN Ver en el mapa Región East of England East Anglia Cambridgeshire CC Tipo de actividad Research Organisations Contacto administrativo David Davison (Mr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos